Erlamide 60mg Tablet
Rx RequiredSalt Composition: Apalutamide
Expiry Date: 01/2028
Buy at $214.41
Inclusive of all taxes
60 Tablet in Bottle
About The Product
Prostate Cancer
Erlamide 60mg Tablet is a prescription-based anticancer medicine. This drug is given to patients who have been diagnosed with early-stage prostate cancer. This drug blocks the testosterone (Male sex hormone), which is responsible for cancer cell multiplication. Eventually, it slows down the growth of cancer cells and improves the overall quality of the patient's life. This medicine is also used as a combination drug in chemotherapy to increase its effectiveness.
Description
Erlamide 60mg Tablet is an anticancer drug with an active ingredient called Apalutamide. The doctor prescribes this medication to those who are detected with early-stage metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer that has spread to other parts of the body and still responds to medical or surgical treatment.
Erlamide 60mg Tablet blocks testosterone secretion from the prostate gland, which promotes the growth of cancer cells. As a result, the Erlamide tablet shrinks the tumor cells and slows its progression.
It is recommended to take proper consultation with your doctor before using it. Your doctor will decide the dosage and duration of taking the Erlamide 60mg Tablet.
Taking it in the wrong way can cause severe side effects. Consult with your medical professional if you've chest pain, indigestion, seizures, or feel any numbness in your body.
It is advised to use reliable methods of birth control and contraceptive pills to avoid pregnancy while under treatment of Erlamide 60mg Tablet. This medicine may cause infertility in males.
Men should not become fathers or donate sperm during or for 3 months after the last dose of Erlamide 60mg Tablet.
Side Effects
- Like other anticancer medicines, Erlamide 60mg Tablet has mild to severe side effects.
- These are undesired symptoms observed in the body after taking this tablet.
- Usually, they disappear with time as the body adjusts to the medicine.
- These side effects don't need special medical attention, but if you observe them continually, talk to your medical expert.
- Some of them are listed below: Mild side effects: Fatigue Diarrhea Hot flushes Vomiting & Nausea Joint and muscle pain Skin rashes and itching Tiredness and dizziness Weight loss and loss of appetite High blood pressure and sugar level Severe Side effects: Seizures Leukopenia Fractures in bones Swelling in hand and feet Increase in cholesterol level
How To Use
- Erlamide 60mg Tablet is a prescription-based anticancer drug that should be administered orally.
- It is advised to take this tablet after consulting your healthcare expert.
How It Works
Erlamide 60mg Tablet belongs to the class of selective androgen receptor (AR) inhibitor that binds to the androgen receptor binding domain. The growth of prostate cancer relies on the sex hormone androgen.
Cancer becomes resistant to standard hormonal therapies, due to which androgen receptor binds continuously to promote cancer growth. Erlamide 60mg Tablet blocks the signaling pathway, DNA binding, protein transportation in the nucleus, and AR-mediated transcription, which leads to the replication of the cancer cells.
Erlamide 60mg Tablet blocks receptor activation and suppresses them from binding to androgen. In that way, it slows down the growth of the cancer cells.
Safety Advice
Missed Doses
- It is advised not to miss any scheduled dosage of Erlamide 60mg Tablet.
- In case you miss a dose, consult your doctor immediately.
- Don't overdose to compensate for the missed one.
- Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
Quick Tips
Erlamide 60mg Tablet is not recommended in patients with a history of seizures, any brain injury, or a recent stroke (within one year).
Inform your doctor if you have a history of cardiovascular problems before taking Erlamide 60mg Tablet.
Using Erlamide 60mg Tablet makes your skin sensitive and dry. Use high SPF sunscreen before exposing to direct sunlight.
Your healthcare provider will decide how much you take and how often you need Erlamide 60mg Tablet. You are advised to follow the prescription strictly.
Your healthcare expert must measure your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Erlamide 60mg Tablet can cause fluctuations in their levels.
Use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Erlamide 60mg Tablet. Discuss with your healthcare expert the risks and benefits of taking this medicine if you want to conceive in the future.
It is recommended to inform your doctor if you are taking any prescribed and non-prescribed medications, nutritional or vitamin supplements, or herbal products. These drugs can interact with Erlamide 60mg Tablet and may result in some severe side effects.
FAQs
Erlamide 60mg Tablet is not indicated for use in females.
It is used for the treatment of prostate cancer in men.
Reference
Chung, B. H., Huang, J., Uemura, H., Choi, Y.
D., Ye, Z. Q., Suzuki, H., & Uemura, H.
(2023). Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
Asian Journal of Andrology, 25(6), 653-661. Koshkin, V.
S., & Small, E. J.
(2023). Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.
Therapeutic Advances in Urology, 10(12), 445-454. Saad, F., Small, E.
J., Feng, F. Y., Graff, J.
N., Olmos, D., Hadaschik, B. A., & Smith, M.
R. (2025).
Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN. European Urology, 81(2), 184-192.
Small, E. J., Saad, F., Chowdhury, S., Hadaschik, B.
A., Graff, J. N., Olmos, D., & SPARTAN investigators.
(2024). SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
T’jollyn, H., Ackaert, O., Chien, C., Lopez-Gitlitz, A., McCarthy, S., Ruixo, C. P., & Agarwal, N.
(2022). Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
Cancer Chemotherapy and Pharmacology, 89(5), 629-641. Yue, W., Li, C., Wang, T., You, J., Sun, J., Liu, J., & Padanilam, B.
J. (2025).
Circadian rhythm-related miR-6883-5p suppresses enzalutamide-resistant prostate cancer. Non-coding RNA Research.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
